Sawicka-Gutaj Nadia, Stańska Alicja, Stański Marcin, Gruszczyński Dawid, Zawalna Natalia, Pochylski Mateusz, Ruchała Marek
Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.
Department of General Radiology and Neuroradiology, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.
Graefes Arch Clin Exp Ophthalmol. 2025 Jan 3. doi: 10.1007/s00417-024-06716-2.
Graves' disease (GD) and Graves' orbitopathy (GO) are multifactorial disorders with links to the gut microbiome and autoimmunity. It is observed that patients with GD exhibit altered gut microbiome diversity. However, little is known about the role of oral microbiota in GD and GO. This study aims to investigate the impact of oral health and oral sanitation on the clinical course of GO in patients disqualified from glucocorticoid treatment due to oral infections.
We reviewed 188 admissions of 127 patients with GO, hospitalized in a tertiary university hospital. Clinical, biochemical, imaging, ophthalmological, and oral health assessment data from each admission were analyzed. Patients excluded from the glucocorticoids (GCs) therapy due to oral foci of infection had the clinical activity score (CAS) reassessed after three months, and they were divided into two groups: with and without improvement.
Finishing dental treatment in the meantime was the only factor significantly correlated with improvement in these patients (p = 0.041). The secondary finding was that anti-thyroid peroxidase antibodies titer was significantly higher in the group with oral foci of infection considered as a contraindication for GCs (medians 28.50 vs 128.00; p = 0.026), and those patients were more likely to smoke than the group without oral issues (p = 0.024).
The results of our study suggest that monitoring and treating oral diseases may be pertinent in patients with GO and might serve as a supportive treatment strategy for managing the condition.
What is known: There is a recognized link between gut dysbiosis and the autoimmune processes in Graves' Disease (GD) and Graves' Orbitopathy (GO).
Elevated levels of TPOAb have been observed in patients with GO who also have oral foci of infection. Dental treatment has been shown to lead to significant clinical improvements in patients with GO. Maintaining oral hygiene might serve as a supportive treatment strategy for managing GO.
格雷夫斯病(GD)和格雷夫斯眼眶病(GO)是与肠道微生物群和自身免疫相关的多因素疾病。据观察,GD患者的肠道微生物群多样性发生了改变。然而,关于口腔微生物群在GD和GO中的作用知之甚少。本研究旨在调查口腔健康和口腔卫生对因口腔感染而不符合糖皮质激素治疗条件的GO患者临床病程的影响。
我们回顾了在一所三级大学医院住院的127例GO患者的188次入院情况。分析了每次入院的临床、生化、影像学、眼科和口腔健康评估数据。因口腔感染灶而被排除在糖皮质激素(GCs)治疗之外的患者在三个月后重新评估临床活动评分(CAS),并分为两组:改善组和未改善组。
在此期间完成牙科治疗是这些患者病情改善的唯一显著相关因素(p = 0.041)。次要发现是,被视为GCs治疗禁忌的有口腔感染灶的组中,抗甲状腺过氧化物酶抗体滴度显著更高(中位数分别为28.50和128.00;p = 0.026),且这些患者比无口腔问题的组更有可能吸烟(p = 0.024)。
我们的研究结果表明,监测和治疗口腔疾病可能与GO患者相关,并且可能作为管理该疾病的一种支持性治疗策略。
已知信息:肠道菌群失调与格雷夫斯病(GD)和格雷夫斯眼眶病(GO)的自身免疫过程之间存在公认的联系。
在患有GO且有口腔感染灶的患者中观察到TPOAb水平升高。牙科治疗已被证明可使GO患者的临床症状显著改善。保持口腔卫生可能作为管理GO的一种支持性治疗策略。